Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of chronic viral infections and bacterial infections. The Company's antiviral focus is primarily directed at the treatment of chronic viral hepatitis, including hepatitis C virus (HCV) and hepatitis B virus (HBV), and its antibacterial focus is directed toward the treatment of serious hospital-based infections. The Company's most advanced HCV product candidates are based on its proprietary compound isatoribine, which represents a new class of drugs being developed to stimulate the body's natural defense mechanisms and respond to viral infections by activating a receptor, or protein, named Toll-like Receptor 7 (TLR 7).